Viking Therapeutics Inc. (NASDAQ:VKTX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
VKTX Weekly Chart

Old Forum Content for VKTX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $VKTX continued move in the gap, now teesting the overhead 8dEMA.
  • DavidG: @woodman $LLY $VKTX I like your comment that the oral drugs will be used for maintenance once weight loss is achieved with the parenteral forms. Also no physician who uses these has the high adverse reactions cited in the studies because we presccribe these at lower doses based on tolerance not on some artificial timetable dictated by study design.
  • Lou: @Lou $ET $EPD $MPLX $ALNY $BA $ARDX $FTI $FROG $WELL $SRPT $HUMA $DBRG $CAVA $WLDN Omitted my $VKTX (and short puts) and a relatively small position in $FIG.
  • woodman: $VKTX - added this morning as it enters into the big gap.
  • ReneeH: @woodman $VKTX I kinda like that play. Curious to see if LLY pulls back here at the underside of 50d.
  • woodman: @Henry $LLY - 10.5% weight loss in 72 weeks - a year and a half basically. Eh. $VKTX had 12.5% weight loss for its oral in 13 weeks. Subcutaneous remains the version that provides serious weight loss, though. Moreover, at the end of the day, I think it will come down to which of the drugs patients can tolerate and stay on. If you're throwing up, or can't have a BM, or have diharrea, and these can't be managed significantly, you're not going to stay on the drug for long.
  • woodman: $VKTX - potential gap trade as it tries to move into the gap.
  • shoredriver: @woodman $VKTX ...rearranging itself a smidge higher in the bowl....
  • BocaRick: $VKTX up 8% on volume
  • camaro69: @BocaRick $VKTX moving nice. bought this am. seems over done
  • woodman: @shoredriver $VKTX - I'm trading this gap move with toilet brush in hand.
  • shoredriver: $VKTX....La Merde.....np.....
  • Henry: @shoredriver $VKTX We are so obese, a 12% weight loss is only a rounding error
  • traderbren: @Henry $VKTX - LOL...well said!
  • woodman: @Henry $VKTX - The oral is envisioned as a maintenance drug. It was never envisioned to compete with subcutaneous. 12% is actually at the high end of what analysts were thinking. The issue for all the orals is the tolerability. And what we see here is good efficacy at 12% for an oral, but tolerability that, while manageable does have to be managed. Sounds like titration is a key.
  • woodman: $VKTX - absolute pile-driving today on its oral obesity med data. Funny (not ha ha funny, but rather strange) thing is that detractors are comparing an oral version - which the company has said many times is designed for maintenance after losing one' ...
  • ReneeH: @woodman $VKTX $NVO $LLY it's a love hate here, when they move they move....both directions unfortunately. I feel ya.
  • woodman: @ReneeH $VKTX $NVO $LLY - Trading vs investing, too. You can trade anything generally (though see below for biotech, specifically), but investing is a different thing. I think investing in small/mid cap biotech, particularly with no approved drugs, i ...
  • ReneeH: @woodman $VKTX $NVO $LLY 100% agree, thank you. I'm much more of a trader vs investor. With biotech, I've had a few great hits and a lot of disappointment. Very tricky to time just right.
  • DavidG: @woodman $VKTX Company noted that the placebo group had a high dropout rate because of nausea and vomiting also, so this might make the dropout data look arbitrarily high for the treatment group. On the other hand the chart is the ultimate arbiter.
  • woodman: @DavidG $VKTX - Yeah, that's a bit of a stumper for me. Why such high AE %s for some of those placebos?
  • woodman: $VKTX - this linked write-up https://x.com/hataf_capital/status/1957805522742104543 seems like a pretty balanced review without diving too deeply in any one area of discussion or too deeply into the weeds of the data.

    That said, I think it shoul ...
  • joelsg1: @woodman $VKTX $LLY $NVO $LLY is preparing to flood the zone with their pill even before approval. I think it's a mistake to discount the no-needle convenience of the daily pill, but once massive supply is available, it's pretty much Game Over for the competitors, unless there's a huge difference in tolerability. And even on that last point, millions of people continue to take statins because they see immediate improvement in their cholesterol numbers, despite the fact that for many their feet, ankles, leg muscles hurt.
  • woodman: @joelsg1 $VKTX $LLY $NVO - Funny thing is, I know many on the injectibles, and not one of them complains about it. It's such a nothing burger. At least not from a pain standpoint. But yes swallowing a pill is more convenient than dealing with syringes and vials or even autoinjectors.
  • Bs7518: @woodman $VKTX $LLY $NVO Thanks for sharing the article I take the shot once a week and your right the pain is nothing so the pill is import to me but as an investor it is.
  • woodman: Biotech - I'm long 3: $ARDX $VKTX $SRPT.
    $ARDX - Ibsrela (tenapanor for IBS-C) selling very well and growing. It alone merits a higher share price. Xphozah (tenapanor for hyperphosphatemia) is gravy on top for now, but If Xphozah litigation is resolv ...
  • woodman: $VKTX broke and closed above $40 yesterday. It may waggle some, but as Steven Tyler said, I think this train will keep rolling.
  • woodman: $VKTX $ARDX - my biotech footprint is very light these days. These two are the only ones I have.
  • woodman: $VKTX up again as the breakout/run into coming Phase 2 data (for the oral version of its obesity med) continues. I'm significantly long this one starting from ~$30. I suspect from past practice that the company will announce a date for it to provide ...
  • ReneeH: @woodman $VKTX $LLY fantastic catch last week! watching for a long time, missed it but like it mucho. Thank you.
  • woodman: @ReneeH $VKTX $LLY - Thanks. I started building in early-mid July, so it's been a bit of a wait and see.
  • ReneeH: @woodman $VKTX $LLY tough spot here, but tempting. Data has been positive to date, higher quality than $HIMS, could do something "could" big
  • woodman: @ReneeH $VKTX $LLY $HIMS - And bio, in general, is treacherous.
  • woodman: $VKTX is trying to get through resistance here (horizontal resistance from 2/21 and the 200d). If it can get through, it could have a decent run into phase 2 data for its oral obesity med.
  • woodman: $VKTX good volume on this move higher, continuing yesterday's high volume move. I added to my position this morning.
  • woodman: $VKTX - needs to close well and keep up the mo-mo, but I think $44-$45 is the next stop.
  • woodman: $VKTX up on less than impressive $LLY oral weight loss med 72 week data. That said, I don't think this is what will cause a jail break for VKTX. The market is waiting for VKTX to report its own oral data, which folks seem to think will be reported this or next month. I am holding some VKTX for the data.
  • Geewhiz: $VKTX 11% pop on $LLY lack of good numbers on their oral obesity trials??
  • woodman:
  • woodman: @Geewhiz $VKTX $LLY - Correct. I've been holding shares for VKTX's coming oral data. I think it will come this or next month. I wouldn't mind seeing a run starting now on this lackluster LLY data.
  • woodman: @DavidK $SRPT - Biotech is a minefield to begin with and perhaps the easiest of the sectors to lose your dough. Looking at my scars, I'd say it's almost uninvestible and not worth the risk. $VKTX is my only longer than a short term chart trade right now. I have $SANA, too, but that is like any other chart-based trade. But SRPT specifically is a complete mess and I was stupid even to get involved, even if with only a small position. I didn't buy much because of the hot stove effect. Again, the scars....
  • edloessi: @woodman - $VKTX looks to be continuing its upward move
  • woodman: @edloessi $VKTX - Indeed. The run into anticipated data. Locked and loaded. Probably needs a few more weeks at least because it sounds like the contracting company is still cleaning and processing the data. But could come in August. Or not. In the meantime, looks destined to test the overhead 200d.
  • woodman: $VKTX @DavidK - The wait for oral phase 2 top line data continues. The CEO said vaguely 2H25. The company doesn't have the data yet. Their contracting company has the raw data and it's in the process of analyzing and assembling it. Not surprising to me that the CEO is vaguely saying 2H25. One day next month or maybe in the next 3 months, they will drop it. Perhaps without warning. Or, they could do it any of several upcoming conferences/fireside chats. Obesity Week, for example, is in the first week of November. EASD (international diabetes conference) is in September. Some speculate that they are close to getting the data in presentable form and it could come in August. Other speculate later. It doesn't much matter in terms of the storyline for the drug. All fwiw.
  • DavidK: @woodman $VKTX thanks for the update. I have a small position so holding for now until the fat melts away so I can see the picture better . Or should I just fog . FYI , had another epidural yesterday higher up on spine and I am 70% better . 3rd time the charm I hope . Going to Back Dr though Aug 11 for his take . Neighbor who works with nerve Dr I saw months ago ( neighbor ran the study , I also have neuropathy) thinks the pain I still get in legs will require Dr to work on the disc issue which I haven’t gotten a clear diagnosis from anyone yet . MRI was done a few weeks ago.Hitting the golf course this week to test things out
  • woodman: @DavidK $VKTX - 70% better is a nice turn of events. That and a couple transfusions (of the potable kind) should get you around the course. Sorry to hear that you may need work on the disc. If you go that route, I hope that isn't a very involved/risky procedure and/or lengthy recovery. Good luck on the course this week.
  • DavidK: $VKTX-https://stocks.apple.com/AMirFI1q2QcW_7TN-qpJJgg updated report this am on $VKTX
  • woodman: @DavidK $VKTX-https $VKTX - moving well now.
  • DavidK: $VKTX- moving up . Reports after the bell . Not sure that means much one way or the other at this point . Drug trials / approval is the key . Woodman , any updated information?
  • woodman: @DavidK $VKTX - I don't have any new info. Brian Lian tends to be an under-promise/over-deliver CEO. I suspect he'll hold his cards fairly close to the vest. But maybe a tease or some good guidance, who knows? I'm not expecting too much. I am holding a position through.
  • Geewhiz: @DAN $VKTX Please review. Is it back in play?
  • woodman: @Geewhiz $VKTX - You need to know the underlying stories with biotech, in my opinion. There's a lot going on with VKTX in the short to relative short term. Earnings/corporate updates 7/23. Data on its oral iteration of its obesity med anticipated soon. Perhaps the data will come in August (that seems to be the feeling/speculation), and maybe the 7/23 updates will give more guidance on the date for that, unless they end up reporting it in conjnuction with the updates, but I don't think so (more feeling/speculation). Recent options activity is "interesting" and the stock is heavily shorted as well. I'm in at $30s-$31s. But it's a careful dance here and potential minefield.
  • Geewhiz: @woodman $VKTX Appreciate your insight.
  • woodman: $VKTX higher high as it moves out of multi-month consolidation. This may be the start of a data-anticipation run-up, IMO.
  • DavidK: @woodman $VKTX I have a small position and looking to add but can’t figure out a strategy . Help woodman
  • woodman: @DavidK $VKTX - Well, it's biotech, so include in the strategy any of 1,000 ways that you can be blind-sided by something bad, then add in that even good news can cause a sell-off. Okay, I'm being sarcastic/cynical, but biotech as you know is a minef ...
  • DavidK: @woodman $VKTX 👍 thanks . I recall huge investment months ago up in the 80’s I believe . I am sure they are not happy about the current situation
  • woodman: $VKTX trying to move out of a little flag.
  • woodman: $VKTX moved out of its flag, though I'd like to see more volume for the move. I am holding a position.
  • woodman: $VKTX - my current bet is that it continues to run higher into coming data anticipated end of July or in August. A second bet would be on the data. If the data are good, blast off. If not, meltdown. I suspect the data will at least be okay if not pretty good. But it's a risky bet. Even when data are good, counterintuitvely, things can go south. Roll the dice, take your chances. I am currently long VKTX.
  • joelsg1: @woodman $VKTX Brave man, once burned, twice shy.
  • woodman: @joelsg1 $VKTX - I hear you. Right now I'm just in for the run-up. I will probably hold a lesser position for the data, but we'll see. But timing is the problem.
  • DavidK: @woodman $VKTX I have a small position
  • woodman: @DavidK @joelsg1 $VKTX - As you know, there's no trusting biotech.
  • DavidK: $VKTX - getting aroused . Up it goes
  • woodman: @DavidK $VKTX - I've been accumulating for anticipated data end of this month or next month (maybe).
  • DavidK: @woodman $VKTX I bought some Yesterday or Tuesday and just picked up some more .
  • woodman: @DavidK $VKTX - $30.50 is next hurdle. With a sustained move above that, maybe we run to $36ish.
  • woodman: $VKTX @tjv821 @Cjauger - $VKTX is moving up out of consolidation. My hunch is it's a pre-data run. Data on its oral iteration of its obesity med is anticipated late July or August. I am back in this one. Thanks to you both for putting this back on my radar screen.
  • Cjauger: $VKTX breaking out above a well defined low base. Up 11% today
  • tjv821: $VKTX Woodman you still in this?
  • woodman: @tjv821 $VKTX - No. Thanks for the reminder. I think it has oral data coming soon - perhaps late July or August. Perhaps this what is moving the stock.
  • woodman: @tjv821 $VKTX - I'm going to buy a starter.
  • MongosPawn: $VKTX Took a small bite. Perky recently. Been trending up along the 8dma. Up 10% today likely due to another analyst giving this an "overweight" rating. Now above the 50dma. Let's see if it can hold it. Plenty of resistance above.
  • woodman: @MongosPawn $VKTX - I've been watching as well, but I'm just so sick of shitty biotech, particularly this one. But as a chart trade, I suppose it has a chance.
  • curtis: @MongosPawn $VKTX (this is a break out) https://www.tradingview.com/x/7kKNq8xk/ adding to position.
  • champ: $VKTX .... is at $29 ..and they received a #Strong-upgrade this morning, by Cantor Fitzgerald, which is a very large company, they initiates with a Overweight, with as price target at $104...... ........Watch for Entry, for a Hold and Build investment position........ and on $/23....BlackRock took out a large position, 5,031,511 shares...... ....and also on 4/23, they reported a small miss on their earnings.....and they also reported that they were holding $851 million $$$$ in cash....... .....I'm holding a New position this morning and I already added this morning. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
  • woodman: @MongosPawn $VKTX - Funny, the Cantor analysis and particularly its $104 PT that's moving the stock is even less than most of the PTs that have been on this stock forever. Go back to one year ago, for instance, and the PTs ranged from $98 to $138. I guess it's been long enough for everyone to forget all those loft PTs and/or it's gone low enough for everyone to get their hopes up again. As you know, I was quite involved with this stock some time ago. I abandoned ship much higher up. Trade the chart, like you are doing, but don't fall in love. Love can cause a lot of pain, and is almost guaranteed in biotech, lol!
  • Bert953: @MongosPawn $VKTX looks constructive in that price broke above the upper BB and the 50dMA. on volume. there's a slight pullback into lunch time. Earnings 7/23. R1 @ $34.
  • woodman: @Henry $LLY - LLY was able to slow titrate, which should help with tolerance. But the starting dose was low. $GPCR getting an even bigger bounce off the news. It has the same molecule, but safety/tolerance of GPCR's remains an unknown. There are doubts that the tolerance of its version will be good, particularly at high doses. $VKTX down on the LLY news, but it will provide 13 week data later this year and is expected to do even better in 13 weeks than what LLY just did in 40 weeks. I have no position in any of these stocks.
  • joelsg1: $PFE Stopped it's oral anti-obesity pill, 1 less competitor good for $VKTX and $GPCR potential acquisition.
  • woodman: @joelsg1 $PFE $VKTX $GPCR - Yep. Too bad $PFE is still swallowing the $43 billion deal for $SGEN.
  • joelsg1: @woodman $PFE $VKTX $GPCR $SGEN Lost alot of market "weight" there :)
  • joelsg1: $VKTX $GPCR Both up on Roche $5.3B deal to acquire rights to Denmark's Zealand Pharma obesity therapy. Takeout hope springs eternal.
  • joelsg1: $AMGN On this dirty no-good rotten day, some green, my healthcare $AMGN, $GPCR, $VKTX and $COO into E tonight (implied move $5.50).
  • Bert953: @joelsg1 $AMGN $GPCR $VKTX $COO Just got to my desk a few min ago. even though FINVIZ shows the 4 indexes above the opening print, looking at a few watchlists, they were a sea of red. The 2 starter positions I took yesterday were stopped out. As I said yesterday, not really a surprise. Lets see what exciting revelations, along with shock and awe come over the weekend. Not planning on doing anything til next week.
  • woodman: $VKTX - As I cautioned, don't chase biotech buyout rumors, at least in the heat of the moment. They virutally always are sell the pop provided by the rumor/speculation. There was some extremely fishy options action with this on Friday. Someone made a huge killing on the rumor, apparently trading before the rumor got out. I'm not sure the SEC functions in any way to protect retail investors, so I don't expect any theiving pumpers who benefitted to be worried about prosecution.
  • woodman: $VKTX buyout rumors moving the stock. I don't have my BS meter plugged in, so I don't know where the needle is landing.
  • Dig44north: @woodman $VKTX found this: Viking Therapeutics (NASDAQ:VKTX) quickly soared 10% amid some renewed takeover speculation for the biotech firm. There's some renewed speculation Viking (NASDAQ:VKTX) may be a takeover target, according to traders, who cited a Betaville "uncooked" alert that circulated on Friday. Pfizer (PFE) is suggested to be the company looking at VKTX, people told the M&A publication. Morgan Stanley is said to be advising. Viking Therapeutics (NASDAQ:VKTX) has a market cap of $3.5 billion. Developing story ...
  • woodman: @Dig44north $VKTX - Never heard of the outfit.
  • joelsg1: @woodman $VKTX Oh how the mighty have fallen.
  • woodman: @joelsg1 $VKTX - If I had any, I'd be selling the rumor. The final dump on the large majority of my shares was in the 50s and 60s.
  • toothdriller81: $VKTX. Any news?
  • kenb: @toothdriller81 $VKTX Scotiabank analyst coverage - sector outperform with price target $102. I wish it can climb to that.
  • DavidG: @toothdriller81 $VKTX I couldn't find anything substantive. This is the first time in 3.5 months that it has been above the 21d MA. Plenty of brokerage houses have all sorts of opinions but I don't make much of those. Maybe @Woodman might be aware of something?
  • Samara: @DavidG $VKTX Scotia bank initiated coverage with a sector outperform rating w/target of $102.00
  • woodman: @DavidG $VKTX - Lots of theories, because, you know, there's always a reason for a move, right? I don't know anything specifically attributed to this move that I'd call reliable. I saw some references to VK2735 and VK0214 trial recruitments/starts/co ...
  • woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Just saw this. Cowen GLP-1 Market: The Pipeline Expands - Global GLP-1 sales in 2030 could reach $139B, up from our $101B forecast a little over a year ago. The market is maturing but accruing health outcomes data should broaden access and maintain momentum.
  • woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Interesting that VKTX has dropped to a $3.8B market cap, and ended 2024 with a decent cash position of $903 million. But it is running multiple trials now, so it will have to burn a lot.
  • joelsg1: $VKTX E tonight, they started Phase 2 of their weight loss pill, maybe they tell us something.
Visit the Trading Forum to join in the discussion.
Stock Price $38.55
Change -0.05%
Volume 2,739,950

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Request Video of VKTX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!